3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Completed
3
No longer available
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Sarcoma
3
CNS
3
Conditions
Gliosarcoma
3
Glioblastoma
3
Neoplasms
2
Glioma
2
Brain Neoplasms
2
Recurrence
1
Interventions
Temozolomide
203
Radiotherapy
118
Bevacizumab
93
Radiation
40
Magnetic Resonance Spectroscopy
28
Irinotecan
27
Carmustine
25
Surgical Procedures, Operative
24
Lomustine
21
Erlotinib Hydrochloride
19
Chemotherapy, Adjuvant
18
Carboplatin
17
temsirolimus
13
Drug Therapy
13
O(6)-benzylguanine
12
Nivolumab
12
sargramostim
11
Sirolimus
11
Radiotherapy, Intensity-Modulated
11
Radiotherapy, Conformal
11
Sorafenib
10
Radiosurgery
10
Imatinib Mesylate
10
Everolimus
10
pembrolizumab
9
motexafin gadolinium
9
Vorinostat
9
Thalidomide
8
IL13-PE38
8
Gefitinib
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Completed
×
Glioblastoma
×
rindopepimut
×
Clear all
NCT01498328
2020-02-17
ReACT
Celldex Therapeutics
Phase 2
Completed
127 enrolled
NCT01480479
2018-01-16
ACT IV
Celldex Therapeutics
Phase 3
Completed
745 enrolled
NCT00626015
2016-01-21
ZAP IT
Duke University
Phase 1
Completed
16 enrolled